Nifedipine does not alter the pharmacokinetics of venlafaxine enantiomers in healthy subjects phenotyped for CYP2D6, CYP2C19, and CYP3A (2021)
- Authors:
- USP affiliated authors: TOZATTO, EDUARDO - FCFRP ; ROCHA, ADRIANA - FCFRP ; COELHO, EDUARDO BARBOSA - FMRP ; LANCHOTE, VERA LUCIA - FCFRP ; BENZI, JHOHANN RICHARD DE LIMA - FCFRP
- Unidades: FCFRP; FMRP
- DOI: 10.1002/jcph.1745
- Subjects: FÁRMACOS; HIPERTENSÃO; FARMACOCINÉTICA; ANTIDEPRESSIVOS
- Keywords: Venlafaxine,P-gp; Nifedipine; Pharmacokinetics; Enantiomers; Metabolism
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: The Journal of Clinical Pharmacology
- ISSN: 0091-2700
- Volume/Número/Paginação/Ano: v. 61, n. 3, p. 319-327, 2021
- Status:
- Nenhuma versão em acesso aberto identificada
-
ABNT
TOZATTO, Eduardo et al. Nifedipine does not alter the pharmacokinetics of venlafaxine enantiomers in healthy subjects phenotyped for CYP2D6, CYP2C19, and CYP3A. The Journal of Clinical Pharmacology, v. 61, n. 3, p. 319-327, 2021Tradução . . Disponível em: https://doi.org/10.1002/jcph.1745. Acesso em: 08 abr. 2026. -
APA
Tozatto, E., Benzi, J. R. de L., Rocha, A., Coelho, E. B., & Lanchote, V. L. (2021). Nifedipine does not alter the pharmacokinetics of venlafaxine enantiomers in healthy subjects phenotyped for CYP2D6, CYP2C19, and CYP3A. The Journal of Clinical Pharmacology, 61( 3), 319-327. doi:10.1002/jcph.1745 -
NLM
Tozatto E, Benzi JR de L, Rocha A, Coelho EB, Lanchote VL. Nifedipine does not alter the pharmacokinetics of venlafaxine enantiomers in healthy subjects phenotyped for CYP2D6, CYP2C19, and CYP3A [Internet]. The Journal of Clinical Pharmacology. 2021 ; 61( 3): 319-327.[citado 2026 abr. 08 ] Available from: https://doi.org/10.1002/jcph.1745 -
Vancouver
Tozatto E, Benzi JR de L, Rocha A, Coelho EB, Lanchote VL. Nifedipine does not alter the pharmacokinetics of venlafaxine enantiomers in healthy subjects phenotyped for CYP2D6, CYP2C19, and CYP3A [Internet]. The Journal of Clinical Pharmacology. 2021 ; 61( 3): 319-327.[citado 2026 abr. 08 ] Available from: https://doi.org/10.1002/jcph.1745 - Stereoselective pharmacokinetics of lercanidipine by liquid chromatography tandem mass spectrometry
- Estereosseletividade na farmacocinética da Fluvastatina em pacientes diabéticos-hipercolesterolêmicos
- Omeprazole inhibits preferentially the metabolism of the (+)-(S)-citalopram eutomer in healthy volunteers
- Omeprazole preferentially inhibits the metabolism of (+)-(S)-citalopram in healthy volunteers
- Investigation of the in vivo activity of CYP3A in Brazilian volunteers: comparison of midazolam and omeprazole as drug markers
- Development of an enantioselective and biomarker-informed translational population pharmacokinetic/pharmacodynamic model for etodolac
- Enantioselective analysis of etodolac in human plasma by LC–MS/MS: application to clinical pharmacokinetics
- LC-MS/MS analysis of the plasma concentrations of a cocktail of 5 cytochrome P450 and P-glycoprotein probe substrates and their metabolites using subtherapeutic doses
- Changes in tramadol enantioselective pharmacokinetics and metabolism in rats with experimental diabetes treated or not with insulin
- Influence of quinidine, fluvoxamine, and ketoconazole on the enantioseletive pharmacokinetics of citalopram in rats
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
003033039.pdf |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
